Evidence map›Paper›PMID 33029656›Full record

ArticleDiabetologia2020

Type 1 diabetes can present before the age of 6 months and is characterised by autoimmunity and rapid loss of beta cells.

Matthew B Johnson, Kashyap A Patel, Elisa De Franco, William Hagopian, Michael Killian, Timothy J McDonald, Timothy I M Tree, Clara Domingo-Vila, Michelle Hudson, Suzanne Hammersley and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Genetic risk in extremely early onset type 1 diabetes.medRxiv : the preprint server for health sciences · 2025
    Article
  7. Review
  8. Review
  9. Diabetes and women's health.Journal of diabetes investigation · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Matthew B JohnsonInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0002-6519-6687
Kashyap A PatelInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
Elisa De FrancoInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0002-1437-7891
William HagopianPacific Northwest Research Institute, Seattle, WA, USA.
Michael KillianPacific Northwest Research Institute, Seattle, WA, USA.
Timothy J McDonaldInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0003-3559-6660
Timothy I M TreeDepartment of Immunobiology, School of Immunobiology & Microbial Sciences, Kings College London, London, UK.ORCID 0000-0002-6973-5377
Clara Domingo-VilaDepartment of Immunobiology, School of Immunobiology & Microbial Sciences, Kings College London, London, UK.
Michelle HudsonInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0003-0623-1873
Suzanne HammersleyInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
Rebecca DobbsInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
EXE-T1D Consortium
Sian EllardInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
Sarah E FlanaganInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.ORCID 0000-0002-8670-6340
Andrew T HattersleyInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
Richard A OramInstitute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK. R.Oram@exeter.ac.uk.ORCID 0000-0003-3581-8980
University of Exeter · GBKing's College London · GBPacific Northwest Diabetes Research Institute · US

Funding

Department of Health ICA-SCL-2016-02-003Department of Health NIHR-HCS-P12-03-03Diabetes UK DUK-15/0005232Leona M. and Harry B. Helmsley Charitable Trust G-2018PG-T1D049G-2018PG-T1D049Wellcome TrustWellcome Trust 098395/Z/12/ZWellcome trust/Royal Society 105636/Z/14/Z
6 · The paper itself

Abstract

aims/hypothesisDiabetes diagnosed at <6 months of age is usually monogenic. However, 10-15% of affected infants do not have a pathogenic variant in one of the 26 known neonatal diabetes genes. We characterised infants diagnosed at <6 months of age without a pathogenic variant to assess whether polygenic type 1 diabetes could arise at early ages.

methodsWe studied 166 infants diagnosed with type 1 diabetes at <6 months of age in whom pathogenic variants in all 26 known genes had been excluded and compared them with infants with monogenic neonatal diabetes (n = 164) or children with type 1 diabetes diagnosed at 6-24 months of age (n = 152). We assessed the type 1 diabetes genetic risk score (T1D-GRS), islet autoantibodies, C-peptide and clinical features.

resultsWe found an excess of infants with high T1D-GRS: 38% (63/166) had a T1D-GRS >95th centile of healthy individuals, whereas 5% (8/166) would be expected if all were monogenic (p < 0.0001). Individuals with a high T1D-GRS had a similar rate of autoantibody positivity to that seen in individuals with type 1 diabetes diagnosed at 6-24 months of age (41% vs 58%, p = 0.2), and had markedly reduced C-peptide levels (median <3 pmol/l within 1 year of diagnosis), reflecting rapid loss of insulin secretion. These individuals also had reduced birthweights (median z score -0.89), which were lowest in those diagnosed with type 1 diabetes at <3 months of age (median z score -1.98). CONCLUSIONS/

interpretationWe provide strong evidence that type 1 diabetes can present before the age of 6 months based on individuals with this extremely early-onset diabetes subtype having the classic features of childhood type 1 diabetes: high genetic risk, autoimmunity and rapid beta cell loss. The early-onset association with reduced birthweight raises the possibility that for some individuals there was reduced insulin secretion in utero. Comprehensive genetic testing for all neonatal diabetes genes remains essential for all individuals diagnosed with diabetes at <6 months of age. Graphical abstract.

Indexed as

AutoimmunityBiomarkersC-PeptideDiabetes Mellitus, Type 1FemaleGenetic TestingHumansInfantInfant, NewbornInsulin-Secreting CellsMaleBiomarkersC-PeptideAutoimmunityGenetic risk scoreNeonatal diabetesType 1 diabetes

Identifiers

PMID33029656
PMCPMC7641942
OpenAlexW3092448597

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.